Advertisement

Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies)

Published:December 07, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.11.044
      We compared the outcomes of a novel, thin-strut, cobalt-chromium, absorbable, polymer sirolimus-eluting stent (APSES; MiStent) to the durable polymer cobalt-chromium everolimus-eluting stent (EES; Xience). A propensity-matched analysis was performed comparing data from the DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in the Native Coronary Arteries (DESSOLVE) I and II studies, evaluating the APSES to the EES arm of the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents-4 study. Target lesion failure (TLF) and its components were evaluated at 12 months and annually to 3 years; 805 patients (APSES = 153; EES = 652) were included with propensity matching in 204 patients (APSES = 102; EES = 102). APSES compared with EES had lower TLF at 1 year (3.0% vs 8.0%, p = 0.12) driven by a difference in target lesion revascularization (TLR; 1% vs 6%, p = 0.05), with no difference in target vessel myocardial infarction (p = 0.56) or stent thrombosis (p = 0.31). At 3 years, TLF (5.0% vs 12.5%, p = 0.07) and TLR (2.0% vs 8.4%, p = 0.04) remained lower with APSES. By landmark analysis, there was no significant difference in TLF between 1 and 3 years (p = 0.36). In conclusion, in a propensity-matched analysis, the APSES demonstrated reduced clinically indicated TLR rates at 1 and 3 years compared with the durable polymer EES, with minimal accrual of events between 1 and 3 years.
      To read this article in full you will need to make a payment

      References

        • Cassese S.
        • Byrne R.A.
        • Tada T.
        • Pinieck S.
        • Joner M.
        • Ibrahim T.
        • King L.A.
        • Fusaro M.
        • Laugwitz K.L.
        • Kastrati A.
        Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography.
        Heart. 2014; 100: 153-159
        • Finn A.V.
        • Nakazawa G.
        • Joner M.
        • Kolodgie F.D.
        • Mont E.K.
        • Gold H.K.
        • Virmani R.
        Vascular responses to drug eluting stents: importance of delayed healing.
        Arterioscler Thromb Vasc Biol. 2007; 27: 1500-1510
        • Byrne R.A.
        • Joner M.
        • Kastrati A.
        Polymer coatings and delayed arterial healing following drug-eluting stent implantation.
        Minerva Cardioangiol. 2009; 57: 567-584
        • Stefanini G.G.
        • Byrne R.A.
        • Serruys P.W.
        • de Waha A.
        • Meier B.
        • Massberg S.
        • Juni P.
        • Schomig A.
        • Windecker S.
        • Kastrati A.
        Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
        Eur Heart J. 2012; 33: 1214-1222
        • Carlyle W.C.
        • McClain J.B.
        • Tzafriri A.R.
        • Bailey L.
        • Zani B.G.
        • Markham P.M.
        • Stanley J.R.
        • Edelman E.R.
        Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug.
        J Control Release. 2012; 162: 561-567
        • Ormiston J.
        • Webster M.
        • Stewart J.
        • Vrolix M.
        • Whitbourn R.
        • Donohoe D.
        • Knape C.
        • Lansky A.
        • Attizzani G.F.
        • Fitzgerald P.
        • Kandzari D.E.
        • Wijns W.
        First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
        JACC Cardiovasc Interv. 2013; 6: 1026-1034
        • Wijns W.
        • Vrolix M.
        • Verheye S.
        • Schoors D.
        • Slagboom T.
        • Gosselink M.
        • Benit E.
        • Donohoe D.
        • Knape C.
        • Attizzani G.F.
        • Lansky A.J.
        • Ormiston J.
        • DESSOLVE II Investigators
        Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial.
        EuroIntervention. 2014; 10: 1383-1390
        • Byrne R.A.
        • Kastrati A.
        • Kufner S.
        • Massberg S.
        • Birkmeier K.A.
        • Laugwitz K.L.
        • Schulz S.
        • Pache J.
        • Fusaro M.
        • Seyfarth M.
        • Schomig A.
        • Mehilli J.
        • Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators
        Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.
        Eur Heart J. 2009; 30: 2441-2449
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.A.
        • Steg P.G.
        • Morel M.A.
        • Mauri L.
        • Vranckx P.
        • McFadden E.
        • Lansky A.
        • Hamon M.
        • Krucoff M.W.
        • Serruys P.W.
        • Academic Research Consortium
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Wei L.
        • Lin D.
        • Weissfeld L.
        Regression analysis of multivariate incomplete failure time data by modeling marginal distributions.
        J Am Stat Assoc. 1989; 84: 1065-1073
        • Lin D.
        • Wei L.
        • Ying Z.
        Checking the cox model with cumulative sums of Martingale-based residuals.
        Biometrika. 1993; 80: 557-572
        • Attizzani G.F.
        • Bezerra H.G.
        • Ormiston J.
        • Wang W.
        • Donohoe D.
        • Wijns W.
        • Costa M.A.
        Serial assessment by optical coherence tomography of early and late vascular responses after implantation of an absorbable-coating Sirolimus-Eluting stent (from the first-in-human DESSOLVE I trial).
        Am J Cardiol. 2013; 112: 1557-1564
        • Attizzani G.F.
        • Bezerra H.G.
        • Chamie D.
        • Fujino Y.
        • Spognardi A.M.
        • Stanley J.R.
        • Yamamoto H.
        • Mehanna E.
        • Wang W.
        • Carlyle W.C.
        • McClain J.B.
        • Costa M.A.
        Serial evaluation of vascular response after implantation of a new sirolimus-eluting stent with bioabsorbable polymer (MISTENT): an optical coherence tomography and histopathological study.
        J Invasive Cardiol. 2012; 24: 560-568
        • Wang Q.
        • Pierson W.
        • Sood P.
        • Bol C.
        • Cannon L.
        • Gordon P.
        • Saucedo J.
        • Sudhir K.
        Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system.
        J Interv Cardiol. 2010; 23: 26-32
        • Saito S.
        • Valdes-Chavarri M.
        • Richardt G.
        • Moreno R.
        • Iniguez Romo A.
        • Barbato E.
        • Carrie D.
        • Ando K.
        • Merkely B.
        • Kornowski R.
        • Eltchaninoff H.
        • James S.
        • Wijns W.
        • CENTURY II Investigators
        A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial.
        Eur Heart J. 2014; 35: 2021-2031
        • Pilgrim T.
        • Heg D.
        • Roffi M.
        • Tuller D.
        • Muller O.
        • Vuilliomenet A.
        • Cook S.
        • Weilenmann D.
        • Kaiser C.
        • Jamshidi P.
        • Fahrni T.
        • Moschovitis A.
        • Noble S.
        • Eberli F.R.
        • Wenaweser P.
        • Juni P.
        • Windecker S.
        Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
        Lancet. 2014; 384: 2111-2122
        • Windecker S.
        • Haude M.
        • Neumann F.J.
        • Stangl K.
        • Witzenbichler B.
        • Slagboom T.
        • Sabate M.
        • Goicolea J.
        • Barragan P.
        • Cook S.
        • Piot C.
        • Richardt G.
        • Merkely B.
        • Schneider H.
        • Bilger J.
        • Erne P.
        • Waksman R.
        • Zaugg S.
        • Juni P.
        • Lefevre T.
        Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
        Circ Cardiovasc Interv. 2015; 8: e001441
      1. Keriakes D. A prospective randomized investigation of a novel bioabsorbable polymer-coated Everolimus coronary stent—Primary outcomes of the EVOLVE II trial. Presented Late Breaking Trial American Heart Association 2014 on November 19, 2014 in Chicago, IL.

        • Kang S.H.
        • Park K.W.
        • Kang D.Y.
        • Lim W.H.
        • Park K.T.
        • Han J.K.
        • Kang H.J.
        • Koo B.K.
        • Oh B.H.
        • Park Y.B.
        • Kandzari D.E.
        • Cohen D.J.
        • Hwang S.S.
        • Kim H.S.
        Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis.
        Eur Heart J. 2014; 35: 1147-1158
        • Bangalore S.
        • Toklu B.
        • Amoroso N.
        • Fusaro M.
        • Kumar S.
        • Hannan E.L.
        • Faxon D.P.
        • Feit F.
        Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis.
        BMJ. 2013; 347: f6625
        • Lupi A.
        • Rognoni A.
        • Secco G.G.
        • Lazzero M.
        • Nardi F.
        • Fattori R.
        • Bongo A.S.
        • Agostoni P.
        • Sheiban I.
        Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients.
        Eur J Prev Cardiol. 2014; 21: 411-424
        • Nakazawa G.
        • Shinke T.
        • Ijichi T.
        • Matsumoto D.
        • Otake H.
        • Torii S.
        • Hiranuma N.
        • Ohsue T.
        • Otsuka F.
        • Shite J.
        • Hirata K.
        • Ikari Y.
        Comparison of vascular response between durable and biodegradable polymer-based drug-eluting stents in a porcine coronary artery model.
        EuroIntervention. 2014; 10: 717-723
        • Dangas G.D.
        • Serruys P.W.
        • Kereiakes D.J.
        • Hermiller J.
        • Rizvi A.
        • Newman W.
        • Sudhir K.
        • Smith Jr., R.S.
        • Cao S.
        • Theodoropoulos K.
        • Cutlip D.E.
        • Lansky A.J.
        • Stone G.W.
        Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions).
        JACC Cardiovasc Interv. 2013; 6: 914-922
        • Byrne R.A.
        • Kastrati A.
        • Massberg S.
        • Wieczorek A.
        • Laugwitz K.L.
        • Hadamitzky M.
        • Schulz S.
        • Pache J.
        • Fusaro M.
        • Hausleiter J.
        • Schomig A.
        • Mehilli J.
        • ISAR-TEST 4 Investigators
        Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
        J Am Coll Cardiol. 2011; 58: 1325-1331
        • Serruys P.W.
        • Farooq V.
        • Kalesan B.
        • de Vries T.
        • Buszman P.
        • Linke A.
        • Ischinger T.
        • Klauss V.
        • Eberli F.
        • Wijns W.
        • Morice M.C.
        • Di Mario C.
        • Corti R.
        • Antoni D.
        • Sohn H.Y.
        • Eerdmans P.
        • Rademaker-Havinga T.
        • van Es G.A.
        • Meier B.
        • Juni P.
        • Windecker S.
        Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted from A Durable versus ERodable Stent Coating) randomized, noninferiority trial.
        JACC Cardiovasc Interv. 2013; 6: 777-789
        • Kufner S.
        • Byrne R.A.
        • Valeskini M.
        • Schulz S.
        • Ibrahim T.
        • Hoppmann P.
        • Schneider S.
        • Laugwitz K.L.
        • Schunkert H.
        • Kastrati A.
        Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.
        EuroIntervention. 2014;